Leveraging international experience to establish roots in Taiwan

Chih-Ming Chen, Ph.D.: Chairman and CEO

Dr. Chih-Ming Chen serves as chairman since inception of the company, and currently also serves as the CEO. In 1993, Dr. Chen co-founded Andrx Corporation in Florida, USA. Under his leadership, Andrx has filed several significant ANDA’s of controlled-release (CR) oral dosage forms, mostly with PIV in the 90’s. He and his team obtained over 50 patents and more than 20 ANDA approvals of mostly CR products in US. In 2002, Dr. Chen founded his second company, Anchen Pharmaceuticals in Irvine, California with its initial R&D labs in Taiwan, which was spun off and went public in Taipei Exchange in December 2013. Dr. Chen brings his experience in R&D technology of various dosage forms and his business savviness to TWi Pharma and continues to focus on producing niche products. Dr. Chen received his Ph.D. in Pharmacy from Ohio State University and B.S./M.S. degrees in Pharmacy from National Taiwan University.

   Jian-bo Xie: EVP – R&D & COO

Mr. Jian-bo Xie possesses over 20 years of experience in research and development of high-barrier pharma manufacturing process. He completed 8 Paragraph IV ANDA application submissions with specialization in generic controlled release development and high-barrier drugs mass production. Prior to joining TWi, Mr. Xie had senior R&D positions with Andrx, Actavis, and Par Pharmaceuticals. During the time with Par, he led an annual average of 10-12 new R&D projects and achieved an outstanding industry record. Mr. Xie holds 6 US patents. Mr. Xie received his master degree from Shenyang Pharmaceutical University, P.R China.

   Rick Pallokat: EVP – US Commercial Operations

Mr. Rick Pallokat is responsible for TWi US operations. He brings in more than 25 years of sales and marketing experience in the Pharmaceutical industry and has great track records in his generic business career. Prior to joining TWi, Rick worked for Zenith Goldline, Andrx, and most recently DAVA. During his time with DAVA, Rick held various positions, including Sales VP, Operations VP, and Senior VP. He led and managed market development, product sales, supply chain, product pricing, and marketing strategies. He built the sales and marketing team that launched the first generic product for DAVA and accomplished significant business results. Mr. Rick Pallokat graduated from University of Fairleigh Dickinson and received his MBA degree in Marketing.

   Ling-Ying Liaw: SVP - Alliance & Product Development

Ms. L.Y. Liaw has over 35 years of experience in pharmaceutical manufacturing operations and supply chain management, including injectable products development. Ms. Liaw is the Senior Vice President in charge of Alliance, Semi-solid Research and Development in TWi. Prior to joining TWi, she served for U-Liang Pharmaceutical Co., Ltd. and held positions as R&D Manager, Site Director, Sales Director, Marketing Director and Liaison Pharmacist. Ms. Liaw was Chairman for Committee of Regulatory Affairs & Technology of Taiwan Pharmaceutical Manufacturing Association from 2005 to 2012. Ms. Liaw received her master’s degree in Pharmaceutical Chemistry from National Taiwan University.

   David Chou: VP – Production & Technical Service

Mr. David Chou brings in 28 years of manufacturing and management experience for GMP pharmaceutical factory. Prior to joining TWi, David served for Center Laboratories, INC., Canadian Pharmaceutical Laboratories (Pacific) Ltd. and St. Shine Optical Co., Ltd. He was dedicated to process improvement, scaling up and cost control. David joined TWi in 2004 and is in charge of manufacturing, including oral solid, oral liquid/suspension and semisolid product lines. He has successfully led TWi Zhongli-Plant to pass US/FDA inspections for 3 times and commercial production of 4 ANDA products to US market. David received his B.S. degree of Pharmacy from Pharmacy department of Taipei Medical University.

   Cecie Jiang: VP - Global Quality Compliance

Ms. Cecie Jiang brings in over 15 years of experiences of quality management in pharmaceutical products and medical devices. Prior to joining TWi, she served for Novartis, Stryker and Aphena and was in charge of regulatory inspection management, ISO and customer auditing, quality operations, compliance activities, manufacturing transfer, and regulatory cGMPs. Cecei specializes in establishing quality management system and policy to meet FDA requirement. Cecie received her master of Microbiology degree from University of Wisconsin-Madison.

Top